Poster Session Abstracts最新文献

{"title":"Abstract P6-08-22: Racial and ethnic variation inmulti-gene panelgenetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center","authors":"Michael S. Simon, Nadine H Abdallah, H. Assad, Malini Surapaneni, Rachel Reagle, N. Petrucelli, Kristen S Purrington","doi":"10.1158/1538-7445.sabcs19-p6-08-22","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs19-p6-08-22","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80958105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract P5-04-10: Immune and transcriptional signatures of dendritic cell (DC) vaccination combined with chemotherapy in locally advanced, triple-negative breast cancer (TNBC) patients","authors":"Te-Chia Wu, J. O’Shaughnessy, L. Roberts, Jennifer L. Smith, S. Burkeholder, Jennifer P. Finholt, J. Tarnowski, T. Dao, J. Lamont, S. Zurawski, P. Nguyen, Yuanyuan Wang, Kyung In Kim, D. Blankenship, J. Turner, Xuan Wang, F. Marches, M. Levin, M. Grant, G. Zurawski, V. Pascual, J. Banchereau, K. Palucka","doi":"10.1158/1538-7445.sabcs19-p5-04-10","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs19-p5-04-10","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87469241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract P2-13-14: Sexual dysfunction among breast cancer survivors in adjuvant endocrine treatment","authors":"Mia F Andersen, A. Højgaard, Charlotte B Rotboel, A. Jensen","doi":"10.1158/1538-7445.SABCS19-P2-13-14","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS19-P2-13-14","url":null,"abstract":"The majority of women treated for primary breast cancer (BC) will receive adjuvant endocrine treatment (AET). A treatment, which has several side effects with a varying degree of severity. In some cases, they result in impaired quality of life of the breast cancer survivors (BCS). For younger BCS, these side effects are often augmented by the fact, that premenopausal women may turn postmenopausal by the adjuvant chemotherapy. Among the most common side effects are hot flashes, sweating, vaginal dryness and arthralgia. Sexual problems are also common; however, sexual dysfunction (SD), defined as impairments in sexual function causing personal distress, are inadequately described among BCS on AET. Hence, SD may be underreported in both clinical studies and the daily clinic. The primary aim of this study was to estimate the prevalence of clinically relevant SD and to identify possible predictors of SD among BCS on AET. We conducted a cross-sectional survey among BCS who have been treated with AET9s for more than 3 months, with no actual signs of recurrent disease and no previous cancer diagnosis. The survey consisted of questions regarding demographic factors, present and previous symptoms. The following validated questionnaires were used: Female Sexual Function Index (FSFI), Sexual Complaint Screener - Women (SCS-W), Beck Depression Inventory (BDI), International Consultation on Incontinence Modular Questionnaire - Female Sexual Matters associated with Lower Urinary Tract Symptoms (ICIQ-FLUTSsex) and subscales of the Cancer Rehabilitation Evaluation System (CARES). Additionally, data concerning tumor characteristics and cancer treatment were collected from the medical records. In total, 333 women with a mean age of 58.7 years were included in the study, of which 227 were sexually active. All were heterosexual. In the entire cohort, the most prevalent impairments were low libido (54%), anorgasmia (26%) and lack of arousal (25%). Although dyspareunia was the least frequent impairment reported by BCS (21%), it was the most distressing symptom. Urogenital symptoms were common with 47% of the women reporting vaginal dryness and 38% reporting pain with sexual intercourse. The sexually active BCS were younger, more often partnered, and more satisfied with their sexual life before the cancer diagnosis than those women being sexually inactive. Among the 227 sexually active women, 134 (59%) qualified for having SD. Of these 134 women, 78 (58%) perceived the cancer treatment as the primary reason for their sexual problems. In a multivariate analysis, the risk of having SD was significantly associated with experiencing more vaginal dryness and less psychological well-being. Whereas age, relationship satisfaction and duration of AET were not significantly associated with the risk of having SD. In conclusion, SD was highly prevalent among sexually active BCS on AET and was perceived as a long-term side effect of BC treatment by two thirds of BCS with SD. Vaginal","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86687377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract P3-06-04: Clonal evolution of non-malignant proliferative lesions into breast cancers","authors":"T. Nishimura, Kenichi Yoshida, Yukiko Kawata, Y. Takeuchi, N. Kakiuchi, Y. Shiozawa, Kosuke Aoki, M. Hirata, T. Kataoka, T. Sakurai, Satoko Baba, Y. Shiraishi, K. Chiba, K. Takeuchi, H. Haga, S. Miyano, M. Toi, S. Ogawa","doi":"10.1158/1538-7445.SABCS18-P3-06-04","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-P3-06-04","url":null,"abstract":"[Introduction] Non-malignant proliferative lesions in the breast have been implicated in the development of invasive breast cancer. Previous studies showed that adjacent atypical proliferative lesions and breast cancers shared common genetic alterations, suggesting that these evolved from the same ancestral cell. However, the clonal structure of atypical proliferative lesions and their clonal dynamics during progression to cancer are poorly understood. In this study, we compared genetic profiles of normal ducts, non-malignant proliferative lesions and cancers in the same patients to illustrate the clonal evolution of cancer from a non-malignant epithelial cell. [Methods] Multiple samples were collected from different proliferative lesions within the cancer-borne breast, including invasive cancers, using micro-dissection from formalin-fixed, paraffin-embedded surgical specimens. Somatic mutations and copy number alterations (CNAs) were then evaluated by whole exome sequencing. [Results] A total of 39 samples from 6 premenopausal females carrying estrogen receptor-positive cancers were analyzed, where the samples were obtained from normal ducts (N = 5), non-malignant proliferative lesions (N = 9), and non-invasive (N = 21) and invasive (N = 4) cancers. The number of somatic mutations per sample was ranging from 1 to 311 and increased with pathological disease progression. Two cases with bilateral cancers had a pathogenic germline mutation of either BRCA2 or TP53, where no somatic mutations or CNAs were shared by individual proliferative lesions, suggesting multifocal independent cancerous evolutions. By contrast, in the remaining four unilateral cases, no pathogenic germline mutations were detected, but all proliferative lesions, which were separated by a distance of 7-33 mm, shared one or more driver alterations, such as an AKT1 mutation (UID: KU01), a GATA3 mutation (UID: KU03 and KU06), a CBFB mutation (UID: KU06) and concurrent 1q gain and 16q loss (UID: KU02, KU03 and KU06), while harboring private mutations/CNAs of their own. The analysis of phylogenic trees based on the number of shared mutations predicted an early origin of these founder mutations, which frequently predated decades before the onset of cancer. [Conclusions] Early breast cancer development is thought to be shaped by a simultaneous evolution of multiple precancerous clones. It may be multi-focally initiated by a germline mutation, frequently terminated in bilateral cancers. By contrast, in unilateral cases, cancer clones might be derived from a common ancestral clone, which has acquired a driver founder mutation long before the onset of cancer, and undergo independent evolution, giving rise to multiple proliferative lesions, from which invasive cancer finally evolves. Our findings provide unique insight into the early development of breast cancer. Citation Format: Tomomi Nishimura, Kenichi Yoshida, Yukiko Kawata, Yasuhide Takeuchi, Nobuyuki Kakiuchi, Yusuke Shiozawa, Kosuke Ao","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79854418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract PS9-32: Physical activity platform to improve bone health in cancer survivors","authors":"C. Skinner","doi":"10.1200/JCO.2019.37.15_SUPPL.TPS11632","DOIUrl":"https://doi.org/10.1200/JCO.2019.37.15_SUPPL.TPS11632","url":null,"abstract":"e24054 Background: Cancer treatment-induced bone loss and the risk of fractures is a significant burden on national health care with the annual cost of osteoporosis at $25.3 billion. Clinical studies report that moderate-intensity resistance exercises prevent a decline in bone health and reduce complications such as fatigue, muscle wasting, and bone loss. Only a small percentage cancer survivors engage in exercise. Several factors account for this low level of engagement such as poor awareness of the benefits, lack of motivation, and access to exercise programs for cancer survivors. Web- and mobile app-based programs that encourage physical activity can potentially address these problems and can be scaled for dissemination. Methods: Thrivors plus Bone Health (Thrivors+BH) is first-of-its-kind, clinically validated platform of bone health exercises that adapts to a cancer survivor's pain and energy levels with several interactive feedback features. The product has physical activity, mindfulness, nutrition, survivorship resources, and bone health education. The platform's back-end tracks and reports module activity. We conducted a single-blind RCT of 142 breast cancer survivors adherence to a 20-week program of resistance and impact exercises. Participants in the control arm accessed Thrivors Basic which lacked interactive feedback. Results: The primary outcome was higher adherence. High adherence equals completion of at least 40 of 60 recommended exercise sessions during the 20-week intervention. The intervention group showed higher measures of platform usage, duration and activity. Intervention group completed the validated jumping protocol after an 8-week program of strength training to prepare for increased intensity exercises. Although some participants discontinued due to various reasons (time constraints or health complications), the supportive modules and feedback from the PI influenced participants to resume exercise after a period of inactivity. The mean scores in the PAM and SF-36v surveys were higher for the intervention group. Conclusions: The study demonstrates breast cancer survivors' willingness to utilize a digital platform with prescribed exercise routines. Feedback suggests that more personalized and interactive features may encourage a higher frequency of engagement in bone-health specific physical activity. A follow-up study will examine the impact of the exercise program on bone health and the role of coaching to impact sustainable behavior change. Clinical trial information: NCT03651037 .","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85615101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract P3-07-08: Multi-omic predictor of rapid and late relapse in primary triple negative breast cancer","authors":"Y. Zhang, W. Nock, S. Asad, E. Adams, J. Singh, A. Damicis, M. Lustberg, A. Noonan, R. Reinbolt, S. Sardesai, J. Vandeusen, R. Wesolowski, N. Williams, B. Ramaswamy, D. Stover","doi":"10.1158/1538-7445.SABCS18-P3-07-08","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-P3-07-08","url":null,"abstract":"Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease. Clinically, we observe three distinct TNBC outcomes: 1) rapid relapse (rrTNBC) characterized by aggressive drug resistant disease; 2) late relapse (lrTNBC) characterized by indolent or treatment responsive disease; and 3) no relapse (NoRTNBC). We hypothesized that distinct clinical and genomic features of primary tumors define rapid versus late relapse in TNBC. Approach: Using three publicly-available datasets (METABRIC, TCGA, and a prior gene expression meta-analysis), we identified 455 patients diagnosed with primary TNBC with adequate follow-up to be characterized as rrTNBC (relapse or death within 2 years of diagnosis), lrTNBC (relapse or death more than 2 years after diagnosis), or NoRTNBC (no relapse/death with at least 5 years follow-up). We compiled basic clinical (n=455 patients) and primary tumor multi-omic data, including whole transcriptome (n=455), whole genome copy number (n=317), and mutation data for 171 cancer-related genes (n=317). We evaluated intrinsic subtypes (PAM50, TNBCtype), 125 gene expression signatures, CIBERSORT immune subsets, copy number, and mutation frequency. Results: We first evaluated patients with relapse (rrTNBC+lrTNBC) vs. NoRTNBC. There was no significant difference in age, grade, stage at diagnosis, or PAM50 or TNBC subtype proportion between relapse and NoRTNBC. Among 125 expression signatures, five immune signatures were significantly higher in NoRTNBCs (FDR p = 0.3, all p Conclusions: Primary TNBC tumors destined for rapid, late, or no relapse reflect distinct genomic features. Anti-tumor immune signatures and subsets are enriched in patients who do not relapse yet no difference in mutational or copy number burden. Relative to rapid relapse TNBCs, late relapse TNBCs are enriched for non-basal tumors, estrogen/luminal expression signatures, and mutations in DNAH11 and PIK3CA. Citation Format: Zhang Y, Nock W, Asad S, Adams E, Singh J, Damicis A, Lustberg MB, Noonan A, Reinbolt R, Sardesai S, VanDeusen J, Wesolowski R, Williams N, Ramaswamy B, Stover DG. Multi-omic predictor of rapid and late relapse in primary triple negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-07-08.","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73997366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract P4-08-03: Looking forward to the TNM 9thedition: Is it time to stage the different breast cancer subtypes as distinct diseases?","authors":"A. Nichol, C. Lohrisch, Lovedeep Gondara, C. Speers, K. Gelmon","doi":"10.1158/1538-7445.SABCS18-P4-08-03","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-P4-08-03","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75825242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract P5-13-02: Not presented","authors":"A. Rositch, Om Ginsburg, L. Huang, C. Chao, K. Visvanathan, N. Masalu","doi":"10.1158/1538-7445.sabcs18-p5-13-02","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs18-p5-13-02","url":null,"abstract":"This abstract was not presented at the conference. Citation Format: Rositch AF, Ginsburg OM, Huang L, Chao CA, Visvanathan K, Masalu N. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-13-02.","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75843206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract P4-04-02: Identifying ERBB-2 activating mutations (mts) in HER2 negative tumors for clinical trials – Impact of institute-wide genomic testing and trial matching on trial enrollment in clinical practice","authors":"Pedro Exman, A. Garrido-Castro, M. Hughes, R. Freedman, Cynthia X. Ma, R. Bose, E. Cerami, N. Wagle, R. Barroso-Sousa, C. D. Fitz, N. Lindeman, L. Macconaill, Brittany L. Bychkovsky, Lloyd, Cr Mackichan, P. Kumari, S. Tolaney, I. Krop, E. Winer, D. Dillon, N. Lin","doi":"10.1158/1538-7445.SABCS18-P4-04-02","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-P4-04-02","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75882004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract P2-06-14: The role of SLC7A5 (LAT1) in endocrine therapy-resistant breast cancer","authors":"CM Sevigny, S. Sengupta, Z. Luo, L. Jin, D. Pearce, R. Clarke","doi":"10.1158/1538-7445.sabcs18-p2-06-14","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs18-p2-06-14","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74482588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}